Duovir N (lamivudine/zidovudine/nevirapine) / Hetero, Aurobindo, Viatris, Strides Pharma Science, Macleods, Cipla - LARVOL DELTA

Risk factors for delayed viral suppression on first-line antiretroviral therapy among persons living with HIV in Haiti, 2013-2017. (PubMed, PLoS One) - "In the multivariable analysis, delayed viral suppression was significantly associated with younger age, receiving of care in the Ouest department, treatment with lamivudine (3TC), zidovudine (AZT), and nevirapine (NVP) combined ART regimen, and CD4 counts below 200 cells/mm3. In conclusion, this study was the first to describe and compare differences in delayed viral suppression among PLHIV by geographic department in Haiti. We identified populations to whom public health interventions, such as more frequent viral load testing, drug resistance testing, and ART adherence counseling should be targeted."

Clinical • Journal • Human Immunodeficiency Virus • Immunology • Infectious Disease